Premier Alternatives

Qlaris Bio

Dedham, MA · Founded 2019 · Privately Held (backing)

Developer of novel therapies designed to treat serious and debilitating ophthalmic diseases. Qlaris Bio is based in Dedham, MA and was founded in 2019. Its last reported valuation was $68 million in Apr 2024. It has raised $55 million across 4 recorded rounds; the latest was a $3.9 million seed round in Jun 2026.

Last reported valuation
$68.0M
Oct 2026
Priced at
—
Total raised
$55.0M
Last round
Seed Round
Jun 2026

Qlaris Bio key facts

as of Oct 2026
  • Developer of novel therapies designed to treat serious and debilitating ophthalmic diseases.
  • Qlaris Bio is valued at approximately $68.0M as of Oct 2026 (last reported valuation).
  • It has raised $55.0M across 4 recorded rounds; the latest was Seed Round ($3.9M) in Jun 2026.
  • Notable investors include Correlation Ventures, Canaan Partners, Mayo Clinic, Mayo Clinic Ventures, New Leaf Venture — 6 tracked in total.
  • Qlaris Bio has filed 3 Form Ds with the SEC since 2019, most recently Nov 2025 ($5.6M sold to 8 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$68.0M

Qlaris Bio's last reported valuation, Apr 2024. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Qlaris Bio with a free account
  • ·Watch Qlaris Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Qlaris Bio funding rounds

4 rounds
Jun 2026Seed Round$3.9MSEC filing▮
Nov 2025Early Stage VC$5.6MSEC filing▮
Apr 2024Early Stage VC$24.0MSEC filing▮
Aug 2019Early Stage VC$8.2MSEC filing▮
Full funding history →

Qlaris Bio valuation

Qlaris Bio's last reported valuation was $68 million in Apr 2024. No priced round, secondary trade or fund mark has surfaced since.

How much has Qlaris Bio raised?

Qlaris Bio has raised $55 million across 4 recorded rounds since 2019. The largest was an $8.2 million early-stage round in Aug 2019; the most recent was a $3.9 million seed round in Jun 2026.

Qlaris Bio has filed 3 Form Ds with the SEC since 2019, most recently in Nov 2025 ($5.6 million sold to 8 investors).

Qlaris Bio investors

6 investors are on record for Qlaris Bio, including Correlation Ventures, Canaan Partners, Mayo Clinic and Mayo Clinic Ventures. The seed round in Jun 2026 drew 8 investors.

About Qlaris Bio

Developer of novel therapies designed to treat serious and debilitating ophthalmic diseases. The company's therapies use novel mechanisms of action to potentially serve as an efficacious treatment for high unmet need conditions related to disturbances in intraocular pressure, including a sight-threatening and progressive pediatric rare disease for which effective therapies remain elusive and limited, enabling physicians to get effective and novel therapies for the treatment.

Sector
Healthcare
HQ
Dedham, MA, United States
Founded
2019
Employees
10
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.